From the *Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, †Graduate Institute of Clinical Medicine Science, ‡Department of Biomedical Imaging and Radiological Science, and §School of Medicine, China Medical University, Taichung, Taiwan.
Clin Nucl Med. 2014 Jan;39(1):e104-5. doi: 10.1097/RLU.0b013e3182815f43.
(99m)Tc TRODAT-1, a selective dopamine transporter SPECT imaging agent, has demonstrated its efficacy in identifying patients with Parkinson disease. Primary or metastatic brain neoplasm uptake of TRODAT-1 is rarely reported in literatures. A 51-year-old female patient underwent TRODAT-1 study for bradykinesia and altered cognitive function; the images showed abnormal extrastriatal uptake in the right frontal lobe subsequent to operation, and pathological examination confirmed anaplastic oligodendroglioma. Care should be taken in interpreting TRODAT-1 image; any focus on abnormal accumulation of radiotracer should not be overlooked because it can be brain neoplasm as demonstrated in this case.
(99m)Tc TRODAT-1，一种选择性多巴胺转运体 SPECT 成像剂，已证明其在识别帕金森病患者方面的有效性。在文献中很少有报道 TRODAT-1 摄取原发性或转移性脑肿瘤。一位 51 岁女性患者因运动迟缓和认知功能改变接受 TRODAT-1 研究；图像显示术后右侧额叶出现异常的纹外摄取，病理检查证实为间变性少突胶质细胞瘤。在解释 TRODAT-1 图像时应谨慎；不应忽视任何异常放射性示踪剂聚集的焦点，因为正如本例所示，这可能是脑肿瘤。
